Advertiser Information
Advertising Sales
Timothy Wolfinger, National Account Manager, PMI, Inc.
Phone: 917-710-8535
E-mail: twolfinger{at}pminy.com
Jill Redlund, National Account Manager , PMI, Inc.
Phone: 212-904-0366
E-mail: jredlund{at}pminy.com
Special Sales
Joann Mitchell, Senior Account Manager,
Sponsored Supplements, Microsites, and Custom
Projects
Phone: 781-388-8345
E-mail: joamitchel{at}wiley.com
AlphaMed Press / The Oncologist Journal
318 Blackwell St, Ste 260
Durham, North Carolina 27701-2884 USA
Phone: (919) 680-0011
Fax: (919) 680-4411
E-Mail: theoncologist{at}alphamedpress.com
Current Issue
From the Cover
- Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
- Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion
- Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma
- E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors
- Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile
- Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience
- Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab
- Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)
- Cervical Cancer in Ethiopia: The Effect of Adherence to Radiotherapy on Survival
- Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study)
- Recent Advances in the Treatment of Peripheral T-Cell Lymphoma
- Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers
- Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
- Families' Sense of Abandonment When Patients Are Referred to Hospice
- Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials
- CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
- “Hey Mom, Now I'm Officially an Oncologist”
- The Emerging Impact of Social Media on Cancer Patient Education in Japan
- Interleukin-2 Can Cure Kidney Cancer
- Submit a Manuscript
- INFORMATION FOR
- Contributors
- Subscribers
- Advertisers
- FEATURED CONTENT
- irAEs Series
- Clinical Trial Results
- Conference Perspectives
- Chabner Colloquium
- Discussions with Don S. Dizon
- The Oncologist in Europe
- SERVICES
- Contact Us
- Reprints & Permissions
- Newsletter Sign Up
- Mobile App
- About The Oncologist
- Editorial Board
- Terms of Use
- Privacy Policy
Most
-
Most Read
- Preventing and Managing Toxicities of High-Dose Methotrexate
- New Oral Anticoagulants and the Cancer Patient
- Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
- Malignant Peripheral Nerve Sheath Tumors
- Clinical Signs of Impending Death in Cancer Patients
-
Most Cited
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
- Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
- Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
- Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
